Want to see IFRX full AI Analyst Report?
Top Page
InflaRx
(NASDAQ:IFRX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.50
▲(57.23% Upside)
Action:Reiterated
Date:06/30/26
The score is primarily constrained by weak financial performance, including minimal revenue, continued losses, and sustained cash burn, despite low balance-sheet leverage. Technicals are moderately supportive due to price trading above key moving averages, but mixed momentum indicators prevent a stronger technical score. Valuation contributes limited insight because the company is loss-making and offers no dividend yield data.
Positive Factors
Low financial leverage
InflaRx's negligible debt reduces balance-sheet credit risk and preserves financial flexibility for a clinical-stage biotech. Low leverage limits interest burden and bankruptcy risk, enabling capital deployment into R&D or partnerships without heavy fixed-payment obligations over the medium term.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow indicates the company is consuming cash to finance operations and trials rather than generating it. Over 2–6 months this drives depletion of reserves, forces financing activity, and constrains discretionary R&D or business-development investments unless offset by fresh capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
InflaRx's negligible debt reduces balance-sheet credit risk and preserves financial flexibility for a clinical-stage biotech. Low leverage limits interest burden and bankruptcy risk, enabling capital deployment into R&D or partnerships without heavy fixed-payment obligations over the medium term.
Read all positive factors
InflaRx (IFRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$303.42M
Dividend YieldN/A
Average Volume (3M)1.29M
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees74
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.61
Shares Outstanding147,292,860
10 Day Avg. Volume1,672,983
30 Day Avg. Volume1,291,891
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.39
Price to Sales (P/S)1972.04
P/FCF Ratio-1.70
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue3.41K
Enterprise Value/Gross Profit-13.82
Enterprise Value/Ebitda-2.36
Forecast
1Y Price Target
$8.80Price Target Upside453.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$15.50K
InflaRx Business Overview & Revenue Model
Company Description
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical ro...
How the Company Makes Money
InflaRx is a clinical-stage biotech, so it typically does not have recurring commercial product sales unless it has an approved, marketed drug (null if not applicable). Its funding and revenue, when present, generally come from (1) collaboration a...
InflaRx Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.33K | 29.33K | 165.79K | 63.09K | 0.00 | 0.00 |
| Gross Profit | -7.23M | -7.24M | -3.15M | -469.17K | 0.00 | 0.00 |
| EBITDA | -42.36M | -45.16M | -45.55M | -42.06M | -28.84M | -44.94M |
| Net Income | -42.91M | -45.63M | -46.06M | -42.67M | -29.48M | -45.63M |
Balance Sheet | ||||||
| Total Assets | 48.94M | 55.19M | 76.02M | 120.21M | 102.40M | 125.14M |
| Cash, Cash Equivalents and Short-Term Investments | 39.84M | 46.44M | 18.38M | 12.77M | 81.81M | 83.41M |
| Total Debt | 823.88K | 897.53K | 805.09K | 1.12M | 1.36M | 1.43M |
| Total Liabilities | 12.01M | 13.65M | 14.60M | 17.63M | 14.05M | 19.86M |
| Stockholders Equity | 36.93M | 41.54M | 61.42M | 102.58M | 88.35M | 105.28M |
Cash Flow | ||||||
| Free Cash Flow | -28.93M | -34.03M | -48.60M | -37.89M | -33.91M | -39.97M |
| Operating Cash Flow | -28.81M | -33.92M | -48.56M | -37.81M | -33.74M | -39.94M |
| Investing Cash Flow | -8.18M | 3.11M | 52.36M | -17.70M | 19.36M | -25.95M |
| Financing Cash Flow | 6.23M | 32.00M | 386.45K | 52.99M | 1.94M | 61.58M |
InflaRx Technical Analysis
Neutral
1.59
Price Trends
2.15
Negative
1.60
Positive
1.38
Positive
Market Momentum
0.04
Negative
50.47
Neutral
27.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Neutral. The current price of 1.59 is below the 20-day moving average (MA) of 1.96, below the 50-day MA of 2.15, and above the 200-day MA of 1.38, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 50.47 is Neutral, neither overbought nor oversold. The STOCH value of 27.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IFRX.
InflaRx Risk Analysis
InflaRx disclosed 82 risk factors in its most recent earnings report. InflaRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
InflaRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $171.07M | 1.54 | 55.29% | ― | -100.00% | ― | |
52 Neutral | $303.42M | -2.95 | -94.90% | ― | ― | ― | |
52 Neutral | $79.86M | ― | 233.93% | ― | -61.71% | -11.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $89.61M | -14.83 | 25.68% | ― | -88.41% | 76.14% | |
| ― | $109.55M | -10.29 | -65.73% | ― | ― | 19.64% | |
46 Neutral | $195.01M | ― | -123.07% | ― | ― | 3.91% |
* Healthcare Sector Average
IFRX
InflaRx
2.05
1.16
129.82%
ORMP
Oramed Pharm
4.04
2.05
103.53%
ATRA
Atara Biotherapeutics
9.76
0.46
4.95%
ANIX
Anixa Biosciences
3.06
-0.14
-4.38%
CLNN
Clene
6.27
2.54
68.10%
ABOS
Acumen Pharmaceuticals
2.63
1.14
76.51%
InflaRx Corporate Events
InflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026
May 7, 2026
On May 6, 2026, InflaRx N.V. signed an underwriting agreement with Guggenheim Securities for an underwritten public offering of 75 million ordinary shares at $2.00 per share, which closed on May 7, 2026. The transaction, conducted under the compan...
InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029
May 6, 2026
On May 6, 2026, InflaRx announced a strategic focus on developing its oral C5a receptor inhibitor izicopan for ANCA-associated vasculitis, a life-threatening kidney disorder, with Phase 2 planning under way and multiple development paths being eva...
InflaRx Files Q1 2026 Financials with SEC via Form 6-K
May 6, 2026
InflaRx N.V. has filed a Form 6-K with the U.S. Securities and Exchange Commission for May 2026, incorporating its latest unaudited condensed consolidated financial statements and management’s discussion and analysis for the quarter ended Ma...
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study
May 4, 2026
On May 4, 2026, InflaRx reported new preclinical data showing that its investigational C5aR1 inhibitor izicopan generates minimal reactive metabolites in human liver microsomes, suggesting a low level of bioactivation in this in vitro assay. React...
InflaRx Regains Nasdaq Minimum Bid Price Compliance, Securing Listing Status
Apr 28, 2026
InflaRx N.V., a Nasdaq-listed biopharmaceutical group based in Germany and the U.S., focuses on anti-inflammatory drugs that inhibit the complement activation factor C5a and its receptor, C5aR. Its lead candidate is izicopan, an oral C5a receptor ...
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM
Apr 23, 2026
On April 23, 2026, InflaRx held its annual general meeting of shareholders, where investors approved the Dutch statutory annual accounts for the year ended December 31, 2025, and reappointed KPMG Accountants N.V. as external auditor for 2026. Shar...
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition
Apr 9, 2026
On April 9, 2026, InflaRx reported new in vitro mechanistic data showing that its lead candidate izicopan does not exhibit time-dependent inhibition of CYP3A4, a key enzyme involved in metabolizing many drugs and a common source of drug–drug...
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
Apr 2, 2026
On April 2, 2026, InflaRx N.V. announced it had convened its 2026 annual general meeting of shareholders for April 23, 2026 in Amsterdam, setting March 26, 2026 as the record date and outlining attendance and proxy procedures for registered and be...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.